FDA Clears GE HealthCare’s Next‑Gen SIGNA MRI Systems and AI Workflow Ecosystem

GE HealthCare said in an announcement that it received U.S. FDA 510(k) clearance for three SIGNA offerings: SIGNA Sprint with Freelium (described as a 1.5T sealed magnet configuration), SIGNA Bolt (a 3T system), and SIGNA One (an AI-driven workflow ecosystem). These products are not CE marked and are not available for sale in all regions.

The 510(k) language spans both scanner platforms and associated workflow components. GE HealthCare states that SIGNA One “represents features and content” that are 510(k) cleared with SIGNA Bolt and SIGNA Sprint with Freelium, tying the workflow ecosystem’s cleared status to use alongside those named systems. The release also characterizes SIGNA Sprint with Freelium as a sealed configuration of SIGNA Sprint Select and notes that SIGNA Sprint Select is 510(k) cleared by the FDA. The regulatory footnotes repeat that the systems and SIGNA One are not CE marked and are not available for sale in all regions.

For SIGNA Sprint with Freelium, the release foregrounds siting flexibility and magnet autonomy as key operational themes. GE HealthCare describes the system as a sealed magnet design that uses “less than 1% helium” compared with conventional magnets and reports “>5-hour ride-through time,” which it says enables the magnet to withstand short and prolonged power outages to avoid disruption. The description also labels the magnet “ventless,” stating that this enables installation “virtually anywhere,” from major hospitals to remote regions. The release further attributes autonomous magnet monitoring, protection, and recovery to intelligent sensors that can automate ramp-down and ramp-up processes without requiring a field engineer, presenting these as features intended to support uptime and reduce service dependency.

For SIGNA Bolt, GE HealthCare describes an advanced 3T scanner positioned for “research-level performance,” centered on an 80/200 gradient system and accompanied by quantified infrastructure and energy statements. In the release, the company reports approximately 30% lower gradient power consumption compared with previous-generation systems, alongside an “up to 65%” reduction in peak power demand and “up to 34%” reduction in minimum equipment room space (also compared with previous-generation systems).

In the same portfolio framing, the release lists SIGNA One workflow elements including an automated camera with AI-enabled anatomical landmark localization, in-room consoles, contactless respiratory and peripheral gating, and patient positioning verification. GE HealthCare characterizes these as workflow solutions that may reduce training time and variability.

Key Takeaways:

• The release reports U.S. FDA 510(k) clearance for SIGNA Sprint with Freelium, SIGNA Bolt, and SIGNA One, and notes the products are not CE marked and not available for sale in all regions.
• The release describes SIGNA Sprint’s sealed Freelium magnet with ventless installation positioning and automated monitoring with ramp-down/ramp-up, alongside specific helium-use and ride-through characterizations.
• The release attributes SIGNA Bolt with quantified power and footprint efficiencies and presents SIGNA One as an AI workflow ecosystem with features the company says may help reduce training time and variability.